ALAMEDA, Calif., May 22 -- Xenogen Corp. announced today it has entered into an agreement with Biogen Inc. to evaluate Xenogen's proprietary real-time in vivo imaging technology in their discovery research programs. This technology is expected to enhance the efficiency of Biogen's drug discovery efforts. Under the terms of the agreement, Biogen is licensed to practice Xenogen's real-time in vivo imaging technology, using Xenogen's IVIS imaging system and Living Image software package, and will receive access to some of Xenogen's Bioware cells and in-vivo models. Xenogen's real-time in vivo imaging technology platform is in use at biotechnology and pharmaceutical companies and academic laboratories. Research applications include enhancing drug discovery and development through the use of more predictive and physiologically relevant in vivo systems earlier in the drug development cycle than was previously possible, enabling researchers to better understand diseases. Xenogen's IVIS system is an ultrasensitive camera used with proprietary hardware and Living Image software to noninvasively detect, quantify and manage emitted light from within a living animal; from Bioware cells and microorganisms -- tumor cell lines, bacteria and fungi modified to emit light; and from in-vivo models -- bioluminescent in-vivo models that emit light when target genes are active. For more information, visit: www.xenogen.com